

Paper No. ____
Date Filed: Feb. 6, 2017

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

JANSSEN ONCOLOGY, INC.,
Patent Owner.

Case IPR2016-01332
Patent 8,822,438

JOINT NOTICE OF CHANGE TO DUE DATE 1

Mylan Pharmaceuticals Inc. (“Petitioner”) and Janssen Oncology, Inc. (“Patent Owner”) have conferred and reached an agreement regarding the extension of Due Date 1 as set forth in the Scheduling Order issued on January 10, 2017 (Paper No. 22). In light of the above, the parties jointly request entry of the following changes to the schedule:

	Previous Due Date	Newly Stipulated Date
DUE DATE 1	Mar. 1, 2017	Mar. 8, 2017

Respectfully submitted,

Date: Feb. 6, 2017

By: Dianne B. Elderkin/

Dianne B. Elderkin
Registration No. 28,598
Counsel for Patent Owner

Date: Feb. 6, 2017

By: Brandon M. White/ (with consent)

Brandon M. White
Registration No. 52,354
Counsel for Petitioner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **JOINT NOTICE OF CHANGE TO DUE DATE 1** was served on counsel of record on February 6, 2017 by filing this document through the End-to-End System, as well as delivering a copy via electronic mail to counsel of record for the Petitioner at the following addresses:

Brandon M. White – bmwhite@perkinscoie.com
Bryan D. Beel – bbeel@perkinscoie.com

Respectfully submitted,

Date: Feb. 6, 2017

/Dianne B. Elderkin/
Dianne B. Elderkin
Registration No. 28,598
Counsel for Patent Owner